Pan Xin, Ye Fang, Ning Peiruo, Yu Yiping, Zhang Zhiyi, Wang Jingxuan, Chen Geng, Wu Zhangsong, Qiu Chen, Li Jiancheng, Chen Bangning, Zhu Lizhe, Qian Chungen, Gong Kaizheng, Du Yang
Department of Cardiology, Institute of Cardiovascular Disease, Yangzhou Key Lab of Innovation Frontiers in Cardiovascular Disease, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Kobilka Institute of Innovative Drug Discovery, The Second Affiliated Hospital, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Chinese University of Hong Kong, Shenzhen, China.
PLoS Biol. 2025 Apr 15;23(4):e3003126. doi: 10.1371/journal.pbio.3003126. eCollection 2025 Apr.
Hydroxycarboxylic acid receptor 1 (HCAR1), also known as lactate receptor or GPR81, is a class A G-protein-coupled receptor with key roles in regulating lipid metabolism, neuroprotection, angiogenesis, cardiovascular function, and inflammatory response in humans. HCAR1 is highly expressed in numerous types of cancer cells, where it participates in controlling cancer cell metabolism and defense mechanisms, rendering it an appealing target for cancer therapy. However, the molecular basis of HCAR1-mediated signaling remains poorly understood. Here, we report four cryo-EM structures of human HCAR1 and HCAR2 in complex with the Gi1 protein, in which HCAR1 binds to the subtype-specific agonist CHBA (3.16 Å) and apo form (3.36 Å), and HCAR2 binds to the subtype-specific agonists MK-1903 (2.68 Å) and SCH900271 (3.06 Å). Combined with mutagenesis and cellular functional assays, we elucidate the mechanisms underlying ligand recognition, receptor activation, and G protein coupling of HCAR1. More importantly, the key residues that determine ligand selectivity between HCAR1 and HCAR2 are clarified. On this basis, we further summarize the structural features of agonists that match the orthosteric pockets of HCAR1 and HCAR2. These structural insights are anticipated to greatly accelerate the development of novel HCAR1-targeted drugs, offering a promising avenue for the treatment of various diseases.
羟基羧酸受体1(HCAR1),也被称为乳酸受体或GPR81,是一种A类G蛋白偶联受体,在调节人体脂质代谢、神经保护、血管生成、心血管功能和炎症反应中起关键作用。HCAR1在多种类型的癌细胞中高度表达,它在其中参与控制癌细胞代谢和防御机制,使其成为癌症治疗的一个有吸引力的靶点。然而,HCAR1介导的信号传导的分子基础仍知之甚少。在这里,我们报告了人HCAR1和HCAR2与Gi1蛋白复合物的四个冷冻电镜结构,其中HCAR1与亚型特异性激动剂CHBA(3.16 Å)和无配体形式(3.36 Å)结合,HCAR2与亚型特异性激动剂MK-1903(2.68 Å)和SCH900271(3.06 Å)结合。结合诱变和细胞功能测定,我们阐明了HCAR1的配体识别、受体激活和G蛋白偶联的潜在机制。更重要的是,明确了决定HCAR1和HCAR2之间配体选择性的关键残基。在此基础上,我们进一步总结了与HCAR1和HCAR2的正构口袋相匹配的激动剂的结构特征。这些结构见解有望极大地加速新型HCAR1靶向药物的开发,为治疗各种疾病提供一条有前景的途径。